Tumor News and Research

RSS

Disparities in head and neck cancer patients

A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer.

12 Oct 2008

Outlook for Crohn's disease improves due to new therapies

A study led by Mayo Clinic has found that infliximab (Remicade) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

6 Oct 2008

Considerable disparities in survival found among patients with head and neck cancer

A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer.

6 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Cancer treatment by linear accelerator is a reality now in India

The first patient was successfully treated by the state-of-the-art technology in radiotherapy - linear accelerator, which began functioning last week at RR Cancer Institute and Research Centre, Sri Ram Murti Smarak Institute of Medical Sciences (SRMSIMS), Bareilly in India.

5 Oct 2008

Sea birds' DNA may hold keys to aging and cancer, Bucknell researcher says

Chances are, a mouse in the wild will live less than a year before stumbling upon a hungry falcon or feline.

5 Oct 2008

Exelixis files investigational new drug application for anticancer compound

Exelixis, Inc. announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound. XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins, including kinases.

2 Oct 2008

Research suggests doctors should consider kidney-sparing surgery

A study of almost 1,500 kidney cancer patients treated at Memorial Sloan Kettering Cancer Center suggests that surgery to spare as much kidney tissue as possible may improve overall survival in patients who also have reduced kidney function at the time their cancer is diagnosed. The finding is significant because both kidney cancer and decreased kidney function appear to be increasing.

2 Oct 2008

Discovery of genetic link between obesity and colon cancer risk

A new study reveals the first-ever genetic link between obesity and colon cancer risk, a finding that could lead to greater accuracy in testing for the disease, said a researcher at the University of Alabama at Birmingham (UAB).

30 Sep 2008

Innovative technology to improve colon cancer prevention

Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer. The study appears in the October 2008 issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

30 Sep 2008

Immune system hurts as well as fights cancer - discovery could lead to new cancer treatments with fewer side effects

Researchers at the University of Pennsylvania School of Medicine have found that some proteins of the immune system can promote tumor growth.

29 Sep 2008

Existing anti-obesity drugs may be effective against flu, hepatitis and HIV

Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.

29 Sep 2008

New way to control protein activity could lead to cancer therapies

Investigators at the Stanford University School of Medicine have found a way to quickly and reversibly fine-tune the activity of individual proteins in cells and living mammals, providing a powerful new laboratory tool for identifying - more precisely than ever before - the functions of different proteins.

28 Sep 2008

Hybrid nanoparticles image and treat tumors

By combining a magnetic nanoparticle, a fluorescent quantum dot, and an anticancer drug within a lipid-based nanoparticle, a multi-institutional research team headed by members of the National Cancer Institute's (NCI) Alliance for Nanotechnology in Cancer has created a single agent that can image and treat tumors. In addition, this new nanoparticle is able to avoid detection by the immune system, enabling the particle to remain in the body for extended periods of time.

28 Sep 2008

Targeted nanoparticles map tumor blood supply in 3-D, assess therapy

One of the defining characteristics of solid tumors is the development of a network of new blood vessels to nourish the rapidly reproducing malignant cells. Now, using a nanoparticle targeted to those new blood vessels, a joint academic-industrial research team, led by investigators from the Siteman Center of Cancer Nanotechnology Excellence, has developed a way to construct a three-dimensional (3-D) map of tumor-induced angiogenesis and monitor the effects of drug therapies on those new blood vessels.

28 Sep 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Multifunctional polymer nanoparticles pass critical in vivo test

In an effort to overcome the drug resistance that often occurs in cancer, a team of investigators has developed a nanoparticle made of a blend of polymers that first releases a powerful anticancer drug and then delivers an agent that tricks a drug-resistant cell into committing suicide. Now, tests in mice with human breast cancer have shown that these blended nanoparticles are effective in maintaining high levels of both drugs in the vicinity of tumors.

28 Sep 2008

Nanobubbles deliver targeted cancer drugs using ultrasound

Using a combination of polymers that respond to temperature, a research team at the University of Utah has developed a multifunctional nanoparticle that can image tumors using ultrasound and simultaneously deliver cell-damaging energy and anticancer drugs to those tumors. In addition, these nanoparticles appear to act specifically on tumors and not on healthy tissue.

28 Sep 2008

Anticancer drug triggers nanoparticle formation, improves stability in vivo

Paclitaxel is a powerful anticancer agent used to treat a variety of malignancies, but severe side effects limit its ultimate effectiveness and utility. To improve this drug's pharmacological properties, researchers have turned to nanoparticle-based delivery agents, although with marginal success; stably trapping large amounts of paclitaxel in most nanoparticles has proven difficult.

28 Sep 2008

Research provides new insights into how cells accessorize their proteins

St. Jude Children's Research Hospital investigators have gained new insight into how the cell's vast array of proteins would instantly be reduced to a confusion of lethally malfunctioning molecules without a system for proteins to "accessorize" in order to regulate their function.

21 Sep 2008